AI
GBT

ArchPoint Investors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

ArchPoint Investors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-168,725
Closed -$11.5M – 65
2022
Q3 		$11.5M Sell
168,725
-5,040
-3% -$278K 4.69% 5
2022
Q2 		$5.55M Sell
173,765
-4,024
-2% -$118K 2.2% 14
2022
Q1 		$6.16M Sell
177,789
-16,000
-8% -$478K 2.12% 13
2021
Q4 		$5.67M Sell
193,789
-3,000
-2% -$92.9K 1.68% 19
2021
Q3 		$5.01M Buy
196,789
+8,281
+4% +$243K 1.5% 16
2021
Q2 		$6.6M Sell
188,508
-10,142
-5% -$396K 2.24% 10
2021
Q1 		$8.1M Sell
198,650
-18,860
-9% -$867K 2.29% 8
2020
Q4 		$9.42M Hold
217,510
– – 2.61% 6
2020
Q3 		$12M Buy
217,510
+27,130
+14% +$1.72M 3.83% 5
2020
Q2 		$12M Buy
190,380
+1,274
+0.7% +$87.4K 3.85% 4
2020
Q1 		$9.66M Buy
189,106
+2,350
+1% +$157K 3.81% 5
2019
Q4 		$14.8M Buy
186,756
+30,521
+20% +$1.81M 4.54% 4
2019
Q3 		$7.58M Sell
156,235
-400
-0.3% -$20.8K 2.56% 7
2019
Q2 		$8.24M Buy
156,635
+14,950
+11% +$859K 2.61% 7
2019
Q1 		$7.5M Buy
141,685
+2,000
+1% +$98.3K 2.24% 7
2018
Q4 		$5.73M Buy
139,685
+10,250
+8% +$384K 1.99% 7
2018
Q3 		$4.92M Buy
129,435
+40,595
+46% +$1.8M 1.34% 16
2018
Q2 		$4.02M Buy
88,840
+82,840
+1,381% +$3.77M 1.16% 18
2018
Q1 		$290K Buy
6,000
+3,500
+140% +$195K 0.09% 86
2017
Q4 		$98K Buy
+2,500
New +$93.4K 0.03% 100

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

ArchPoint Investors's GBT Position: Q4 2022 in Review

ArchPoint Investors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 168,725 shares — an estimated $11.5M sold.

ArchPoint Investors first reported a position in GBT in Q4 2017 and held it in 20 quarters. The position peaked at $14.8M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • ArchPoint Investors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • ArchPoint Investors sold 168,725 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $11.5M.
  • ArchPoint Investors first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 20 quarters.
  • ArchPoint Investors's Global Blood Therapeutics, Inc. position peaked at $14.8M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on ArchPoint Investors's 13F filing for Q4 2022, filed 13 Feb 2023.